← 返回

革新肿瘤学:人工智能(AI)作为抗体设计与优化工具的作用

英文原题:Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools.

查看英文原题

Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools.

PubMed 2025/03/29(内容时间) Biomark Res Q1 · IF 14.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

抗体在人体抵御疾病(包括癌症等危及生命的疾病)方面发挥关键作用。抗体介导针对外源抗原,有时也针对自身抗原的免疫应答。随着时间推移,抗体技术从单克隆抗体(mAb)发展到CAR-T(CAR-T)细胞,显著影响了生物技术、诊断和治疗。尽管这些进展改进了治疗干预,人工智能(AI)的融入正在革新抗体设计和优化。本综述探讨 AI 的近期进展,包括大语言模型(LLM)、扩散模型和生成式 AI 应用;这些技术通过加速从头生成、提高免疫应答精准度和优化治疗效果,改变了抗体发现。借助先进数据分析,AI 可预测和设计抗体序列、三维结构、互补决定区(CDR)、抗原结合位点(paratope)、表位及抗原-抗体相互作用。这些 AI 创新应对了抗体开发长期存在的挑战,显著提高治疗设计的速度、特异性和准确性。AI 将计算技术进展与生物医学应用结合,推动下一代癌症疗法,变革精准医学并改善患者结局。

展开英文摘要原文

Antibodies play a crucial role in defending the human body against diseases, including life-threatening conditions like cancer. They mediate immune responses against foreign antigens and, in some cases, self-antigens. Over time, antibody-based technologies have evolved from monoclonal antibodies (mAbs) to chimeric antigen receptor T cells (CAR-T cells), significantly impacting biotechnology, diagnostics, and therapeutics. Although these advancements have enhanced therapeutic interventions, the integration of artificial intelligence (AI) is revolutionizing antibody design and optimization.

This review explores recent AI advancements, including large language models (LLMs), diffusion models, and generative AI-based applications, which have transformed antibody discovery by accelerating de novo generation, enhancing immune response precision, and optimizing therapeutic efficacy. Through advanced data analysis, AI enables the prediction and design of antibody sequences, 3D structures, complementarity-determining regions (CDRs), paratopes, epitopes, and antigen-antibody interactions.

These AI-powered innovations address longstanding challenges in antibody development, significantly improving speed, specificity, and accuracy in therapeutic design. By integrating computational advancements with biomedical applications, AI is driving next-generation cancer therapies, transforming precision medicine, and enhancing patient outcomes.

论文信息

作者
Dewaker V、Morya VK、Kim YH、Park ST、Kim HS、Koh YH
第一作者单位
Institute of New Frontier Research Team, Hallym University, Chuncheon-Si, Gangwon-Do, 24252, Republic of Korea.South Korea
通讯作者单位
Department of Biomedical Gerontology, Ilsong Institute of Life Science, Hallym University, Seoul, 07247, Republic of Korea. kohyh@hallym.ac.kr.South Korea
文献类型
综述
期刊
Biomarker research2025 Mar 29
原文标识
PubMed 40155973 · DOI 10.1186/s40364-025-00764-4